GlobeNewswire: EyePoint Pharmaceuticals, Inc. Contains the last 10 of 283 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T16:19:34ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/18/2847663/0/en/EyePoint-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=27566EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)2024-03-18T11:00:00Z<![CDATA[WATERTOWN, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/03/07/2842099/0/en/EyePoint-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Highlights-Recent-Corporate-Developments.html?f=22&fvtc=4&fvtv=27566EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments2024-03-07T12:00:00Z<![CDATA[– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical trial expected in 2H 2024 –]]>https://www.globenewswire.com/news-release/2024/03/04/2839395/0/en/EyePoint-Pharmaceuticals-Announces-Appointment-of-Ramiro-Ribeiro-M-D-Ph-D-as-Chief-Medical-Officer.html?f=22&fvtc=4&fvtv=27566EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer2024-03-04T12:00:00Z<![CDATA[– Company on-track to report topline data in 2Q 2024 for the Phase 2 PAVIA clinical trial of EYP-1901 in moderately severe-to-severe NPDR –]]>https://www.globenewswire.com/news-release/2024/02/29/2837829/0/en/EyePoint-Pharmaceuticals-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-7-2024.html?f=22&fvtc=4&fvtv=27566EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 20242024-02-29T12:00:00Z<![CDATA[WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 7, 2024 to report its fourth quarter and full-year 2023 financial results and highlight recent corporate developments.]]>https://www.globenewswire.com/news-release/2024/02/27/2835856/0/en/EyePoint-Pharmaceuticals-Announces-Participation-at-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=27566EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences2024-02-27T12:00:00Z<![CDATA[WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that Company management will participate at the following upcoming conferences:]]>https://www.globenewswire.com/news-release/2024/02/16/2830681/0/en/EyePoint-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=27566EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)2024-02-16T12:00:00Z<![CDATA[WATERTOWN, Mass., Feb. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/02/03/2823161/0/en/EyePoint-Pharmaceuticals-Announces-Two-Presentations-of-Topline-Data-with-Additional-Subgroup-Analyses-from-the-Phase-2-DAVIO-2-Clinical-Trial-of-EYP-1901-for-the-Treatment-of-Wet-.html?f=22&fvtc=4&fvtv=27566EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration2024-02-03T21:20:00Z<![CDATA[WATERTOWN, Mass., Feb. 03, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced results from new subgroup analyses from the Phase 2 DAVIO 2 clinical trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E. These data are being presented in two sessions at the Angiogenesis, Exudation, and Degeneration 2024 Meeting held virtually today, February 3, 2024. The presenting speakers are Charles C. Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Texas, and Carl Regillo, M.D., FACS, Professor of Ophthalmology, Thomas Jefferson University.]]>https://www.globenewswire.com/news-release/2024/01/31/2820937/0/en/EyePoint-Pharmaceuticals-to-Present-at-the-Guggenheim-Healthcare-Talks-6th-Annual-Biotechnology-Conference.html?f=22&fvtc=4&fvtv=27566EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference2024-01-31T12:00:00Z<![CDATA[WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that George Elston, Executive Vice President and Chief Financial Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 p.m. ET.]]>https://www.globenewswire.com/news-release/2024/01/16/2809689/0/en/EyePoint-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=27566EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)2024-01-16T12:00:00Z<![CDATA[WATERTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/01/10/2806962/0/en/EyePoint-Pharmaceuticals-Announces-First-Patient-Dosed-in-Phase-2-VERONA-Clinical-Trial-of-EYP-1901-for-the-Treatment-of-Diabetic-Macular-Edema.html?f=22&fvtc=4&fvtv=27566EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema2024-01-10T12:00:00Z<![CDATA[WATERTOWN, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that the first patient has been dosed in the Phase 2 VERONA clinical trial of EYP-1901 for diabetic macular edema (DME). EYP-1901 is an investigational sustained delivery therapy containing vorolanib, a selective tyrosine kinase inhibitor formulated in bioerodible Durasert E.]]>